Connect with us

Hi, what are you looking for?

POZ

Mpox antiviral outcomes are similar regardless of HIV status – study

Mpox patients treated with tecovirimat, an antiviral drug widely used since the last outbreak, had similar outcomes regardless of HIV status.

Photo by brenoanp from Pexels.com

Mpox patients treated with tecovirimat, an antiviral drug widely used since the last outbreak, had similar outcomes regardless of HIV status, according to a study, ‘Tecovirimat Treatment of People with HIV During the 2022 Mpox Outbreak,’ published in Annals of Internal Medicine.

“Columbia and Weill Cornell were two of the early sites in New York City to see patients with mpox, and there was a concern that persons with HIV and mpox would have worse outcomes,” says Jason Zucker, MD, an infectious disease specialist at Columbia University Vagelos College of Physicians and Surgeons and co-leader of the study. “Our study suggests that patients with well-controlled HIV responded to tecovirimat treatment similarly to people without HIV.”

During the outbreak, the CDC allowed for the use of tecovirimat (TPOXX) for people with severe mpox symptoms (through site-specific expanded access investigational new drug applications). The drug was originally developed and approved for the treatment of smallpox, a related virus, but had not been studied in people with mpox.

Study methods and findings

In the current study, the researchers analyzed data from 154 patients at Columbia and Weill Cornell who tested positive for mpox and were treated with tecovirimat between June and August 2022. Of those who were treated, 72 patients had HIV.

Nearly all patients, regardless of HIV status, were pain-free by the end of the treatment regimen. The drug was equally well tolerated in both patient groups.

The findings confirm results of other studies that show tecovirimat is well-tolerated, though additional studies are needed to establish the drug’s effectiveness against mpox.

More data needed on immunocompromised patients with mpox

Evidence has emerged that people who are severely immunocompromised, including those with poorly controlled HIV, are at greater risk for severe illness and death from mpox. “Only four people in the study had low CD4 counts, a sign of poorly controlled HIV, so we weren’t able to compare treatment outcomes in that population,” says Jacob McLean, DO, a postdoctoral clinical fellow in Columbia’s Department of Medicine and first author of the study.

“New York has better social safety programs for people with HIV compared with other states, so we have fewer patients with poorly controlled HIV,” Zucker says. “There are wide disparities in access to care and treatment for people with HIV across the country and in other parts of the world, which feeds into the inequities in mpox diagnosis and treatment and affects outcomes.”

Advertisement. Scroll to continue reading.

Zucker adds that while the mpox outbreak has virtually ceased in the US, cases are on the rise in other countries. Meaning, “we could see a resurgence of mpox if we don’t make efforts to ensure that all vulnerable individuals are vaccinated,” Zucker says. 

Advertisement
Advertisement

Like Us On Facebook

YOU MAY ALSO LIKE

POZ

Drugs that prevent HIV infection have evolved, but new research shows the standard option is still top with patients.

NEWSMAKERS

Gay and bisexual men over the age of 70 were more likely to report having sex with multiple partners than other groups. This is...

Editor's Picks

From 10.5% to 34.1% of men who have sex with men (including gay and bisexual men) engaged in fisting at least once throughout their...

Health & Wellness

If you have sleep apnea or insomnia, sleep specialists have well-vetted guidelines for the best evidence-based treatments. Not so if you have arousal disorders,...

Advertisement